Ovid Therapeutics Files 8-K Current Report

Ticker: OVID · Form: 8-K · Filed: 2025-09-16T00:00:00.000Z

Sentiment: neutral

Topics: sec-filing, 8-k, regulatory-update

TL;DR

Ovid Therapeutics filed a routine 8-K, check for updates.

AI Summary

Ovid Therapeutics Inc. filed an 8-K on September 16, 2025, reporting an event on September 11, 2025. The filing is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934. The company is incorporated in Delaware and its principal executive offices are located in New York, NY.

Why It Matters

This filing indicates a routine update or event disclosure by Ovid Therapeutics Inc. to the SEC, which may contain information relevant to investors.

Risk Assessment

Risk Level: low — This is a standard 8-K filing for a current report, not indicating any immediate financial distress or significant operational change.

Key Numbers

Key Players & Entities

FAQ

What is the specific event being reported in this 8-K filing?

The filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, with the earliest event reported on September 11, 2025. However, the specific nature of the 'Other Events' is not detailed in the provided text.

When was this 8-K form filed with the SEC?

The 8-K form was filed as of date September 16, 2025.

What is Ovid Therapeutics Inc.'s state of incorporation?

Ovid Therapeutics Inc. is incorporated in Delaware.

Where are Ovid Therapeutics Inc.'s principal executive offices located?

The principal executive offices are located at 441 Ninth Avenue, 14th Floor, New York, New York, 10001.

What is the SEC file number for Ovid Therapeutics Inc.?

The SEC file number for Ovid Therapeutics Inc. is 001-38085.

Filing Stats: 418 words · 2 min read · ~1 pages · Grade level 12 · Accepted 2025-09-16 08:00:42

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized Date: September 16, 2025 OVID THERAPEUTICS INC. By: /s/ Jeffrey Rona Jeffrey Rona Chief Business and Financial Officer

View on Read The Filing